To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Celebra Receives Priority FDA Review
URL: http://www.pslgroup.com/dg/AB796.htm
Doctor's Guide
August 25, 1998

ST. LOUIS, MO -- Aug. 25, 1998 -- Monsanto's G.D. Searle & Co.'s Celebra(TM) (celecoxib) has received priority review designation from the United States Food and Drug Administration.

Celebra's submitted indication is for acute or chronic use in the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and for the management of pain. The compound is being submitted as a proposed member of a new class of agents known as specific COX-2 inhibitors.

Searle and Pfizer Inc. will develop and commercialise Celebra in all areas except Japan.

Related Links: Searle & Co., Pfizer Inc.

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.